DRTSFDA said, ‘carry on’
Alpha Tau Medical got the kind of update that can keep a clinical program from getting stuck in the hallway: the FDA cleared the company to complete enrollment in its REGAIN recurrent glioblastoma trial and add two U.S. clinical sites.
That matters because trial momentum is everything in biotech. More sites usually means faster enrollment, a better shot at cleaner data, and less of that awkward “we’re still waiting on patients” energy that markets hate.
The headline number investors will stare at
The company also highlighted early interim results showing 100% local disease control. That’s the sort of stat that makes investors sit up a little straighter, even if it’s early and the sample size is still part of the story.
In other words: this isn’t an approval, and it’s not a guarantee the science will keep singing. But it is a meaningful operational and regulatory checkpoint that could improve the odds of the trial moving forward without bureaucratic speed bumps.
Why you should care
For a clinical-stage name like Alpha Tau, progress often comes in small but important wins:
- the FDA doesn’t slam the door
- enrollment keeps moving
- more sites join the party
- interim data gives the stock something to brag about
Big picture: biotech investors live on a diet of catalysts, and this one just got a little more fuel in the tank.